Trial sponsors have shared these lung cancer clinical trials that are enrolling participants to help advance lung cancer science. Most medications and treatments currently available are thanks to patients who went through clinical trials to prove the effectiveness and safety of the treatment being studied.

Clinical trials have eligibility requirements to join so that participants remain safe, while having a likelihood of success when it comes to treatment.

If you’re interested in joining one of the clinical trials below, make sure to talk with your doctor and ask if they think it would be helpful for your treatment. Some patients may have additional health problems that could be made worse by treatments used in a clinical trial.

Note: The status of each trial may change with time. Please reach out to the contact listed in each trial opportunity to get the most up-to-date information. 

Available clinical trials

  • EDGE-Lung

    Contact:

    510-462-3330 or [email protected]

    This trial will study how stage 4 NSCLC responds to different combinations of potential new treatments being studied, with or without chemotherapy. The potential new treatments being studied in this trial are called domvanalimab, zimberelimab, and quemliclustat. The potential new treatment combinations that each participant receives in the trial will depend in part on whether they have had prior treatment for their NSCLC. It will also depend on whether their tumors have high levels of a protein called “programmed death-ligand 1,” or PD-L1 for short. The amount of PD-L1 present in a person’s cancer cells may affect how their cancer responds to different types of treatment.

    The study is open for the following types of lung cancer:

    • Nonsquamous non-small cell lung cancer
    • Squamous cell lung cancer

    Learn more

*These trials are listed for a period of 3 months.